Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (25691)	9/23/1998 8:40:00 AM
From: Henry Niman	Respond to of 32384

I have linked a couple of MLNM articles to the Biotech Boom table at home.att.net The MLNM/Bayer deal focuses on drug discovery and LGND already has 100 targets, but the MLNM deal will increase competition.

To: jayhawk969 who wrote (25691)	9/23/1998 8:54:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Looks like LGND still heading north. Bid had already been raised to 9 1/8.

To: jayhawk969 who wrote (25691)	9/23/1998 8:59:00 AM
From: Henry Niman	Respond to of 32384

Biotechs did very well yesterday. The SI group showed a gain of over 4%. A similar move was also seen in the IBD Medical-Biomed/Genetics group which contains 184 companies. The group rose 3.8% yesterday, which was the second biggest gain among the 197 Industry Groups covered by IBD.

To: jayhawk969 who wrote (25691)	9/23/1998 9:03:00 AM
From: Henry Niman	Respond to of 32384

MLNM CEO will be on CNBC soon.

To: jayhawk969 who wrote (25691)	9/23/1998 9:51:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

MLNM CEO up next.

To: jayhawk969 who wrote (25691)	9/23/1998 10:10:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

MLNM CEO, Mark Levin, pretty much covered news in press release. Deal includes $130 million in up front payments and is for 5 years to discover 225 targets. Bayer was chosen because of large scale production abilities, and they already have 7 alliances including Hoffman-LaRoche, Astra, and LLY.

To: jayhawk969 who wrote (25691)	9/23/1998 2:27:00 PM
From: Cheryl Galt	Read Replies (2) \| Respond to of 32384

Hi JD! RE: "Small molecule competition heating up." With SO MUCH diverse research needing to be done, and SO LITTLE federal government funding supporting it and so many people waiting and hoping for the potential rewards of such reseach, I just hate to think of Mlnm's WONDERFUL news as COMPETITION. And I don't believe it really is. There's room for many products and COMBINATIONS of products. And -- except possibly for CVD --this list -- "cardiovascular disease, cancer, osteoporosis, pain, liver fibrosis, hematology and viral infections" -- does NOT even mention drugs for METABOLIC conditions (like NIDDM), doesn't mention any endocrinology focus. ----------- Until 1995, there was only ONE CLASS of oral drugs (sulfanyureas, like Glyburide) available in the U.S. for people coping with NIDDM. Today there are at least 4 classes, and other classes are being studied in the lab and the clinic. There is SO much work to be done. Let the generous funding roll to FINALLY accelerate this research. Hopefully this news will stimulate Lilly and others to do likewise . . . (I have to wonder why Lilly let its protege Seragen go under....) Ron Evans' work has given Ligand a powerful focus, that will likely eventually pay off (for sure, for people with NIDDM -- for Ligand, if their cash position gets healthy). I'm not at all worried about competition. Just my .02 Cheryl PS - At 8:30 am my internet connection dropped, leaving the above note languishing on my screen. Apparently, on this beautiful, calm day, US West had a massive power outage in North Seattle, that brought down the phone banks of Eskimo, my friendly little ISP. What an awful, vulnerable, restless feeling to be disconnected from the wide world. I couldn't focus to get anything done! What a RELIEF at 11:18 to be back online. Wow! I see Ligand saw 9.75 today so far!